Extended indication Libmeldy is indicated for the treatment of metachromatic leukodystrophy (MLD) characterized by biall
Therapeutic value Possible added value
Total cost 8,250,000.00
Registration phase Positive CHMP opinion

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information